JW Asset Management's Q4 2022 vs. Q1 2023 13F Holdings: Who They Bought, Who They Sold

JW Asset Management, LLC is a New York-based investment management firm that oversees over $10 billion in assets as of March 31, 2021. As a "13F filer," they are required by the Securities and Exchange Commission (SEC) to submit a Form 13F every quarter. This form discloses their holdings of publicly traded securities with a fair market value of at least $100 million as of the end of the quarter. Let's take a closer look at JW Asset Management's Q4 2022 vs. Q1 2023 13F holdings comparison.

Stocks JW Asset Management Bought

1. NOVO-NORDISK A/S (NVO)

JW Asset Management increased its position in Danish multinational pharmaceutical company Novo Nordisk A/S by 56.2%. They bought 14,100 more shares, bringing their total holdings to 39,100 shares worth $9.4 million.

2. ESTABLISHMENT LABS HLDGS INC (ESTA)

JW Asset Management maintained its position in Establishment Labs Holdings Inc, a Costa Rican-based medical aesthetics company that went public in 2018. They held 3.2 million shares worth $216.3 million.

3. IDAHO STRATEGIC RESOURCES (IDR)

JW Asset Management increased its position in Idaho Strategic Resources, a natural resource exploration company focused on the Western United States, by 6.9%. They bought 54,546 more shares, bringing their total holdings to 271,697 shares worth $1.3 million.

Stocks JW Asset Management Sold

1. MEDICUS SCIENCES ACQUISITION CORP (MSAC)

JW Asset Management completely divested its position in Medicus Sciences Acquisition Corp, a blank-check company that went public in December 2020 with the purpose of acquiring a biotech or medtech company.

2. CELSIUS HLDGS INC (CELH)

JW Asset Management reduced its position in Celsius Holdings Inc, a Florida-based company that produces fitness drinks, by 10.7%. They sold 955 more shares, bringing their total holdings to 86,038 shares worth $8 million.

3. HORIZON THERAPEUTICS PUB LTD (HZNP)

JW Asset Management reduced its position in Horizon Therapeutics Public Limited Company, an Irish-based biopharmaceutical company, by 4.1%. They sold 2,143 more shares, bringing their total holdings to 50,673 shares worth $5.5 million.

Conclusion

JW Asset Management's Q4 2022 vs. Q1 2023 13F holdings comparison shows that they increased their positions in Novo Nordisk A/S, Establishment Labs Holdings Inc, and Idaho Strategic Resources, while divesting completely from Medicus Sciences Acquisition Corp and reducing their positions in Celsius Holdings Inc and Horizon Therapeutics Public Limited Company. It is important to note that these holdings are as of March 31, 2021, and their portfolio may have changed since then. Regardless, following the 13F filings of institutional investors like JW Asset Management can provide valuable insights for individual investors looking to make informed investment decisions.